GLP-1 agonists are not a cure for rheumatic diseases, but they may offer a new approach to managing symptoms and improving outcomes, she said
Molecular and Cellular Endocrinology, 515 , Article 110921
The state obesity drug coverage landscape will continue to evolve as states respond to the recent announcement of the BALANCE model (see Box 1) and as states contend with budget challenges and the federal Medicaid spending cuts in the 2025 reconciliation law
By blocking GSK3-beta, valproic acid allows more beta-catenin to accumulate and reach the nucleus
Olive Oil: Supports bile flow and reduces fat accumulation
Because your body cannot make B12 on its own, you must get it from food, supplements, or medical injections